Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 229 entries
Sorted by: Best Match Show Resources per page
Role of isavuconazole in the treatment of invasive fungal infections.

Therapeutics and clinical risk management

Wilson DT, Dimondi VP, Johnson SW, Jones TM, Drew RH.
PMID: 27536124
Ther Clin Risk Manag. 2016 Aug 03;12:1197-206. doi: 10.2147/TCRM.S90335. eCollection 2016.

Despite recent advances in both diagnosis and prevention, the incidence of invasive fungal infections continues to rise. Available antifungal agents to treat invasive fungal infections include polyenes, triazoles, and echinocandins. Unfortunately, individual agents within each class may be limited...

Cite
Wilson DT, Dimondi VP, Johnson SW, et al. Role of isavuconazole in the treatment of invasive fungal infections. Ther Clin Risk Manag. 2016;12:1197-206doi: 10.2147/TCRM.S90335.
Wilson, D. T., Dimondi, V. P., Johnson, S. W., Jones, T. M., & Drew, R. H. (2016). Role of isavuconazole in the treatment of invasive fungal infections. Therapeutics and clinical risk management, 121197-206. https://doi.org/10.2147/TCRM.S90335
Wilson, Dustin T, et al. "Role of isavuconazole in the treatment of invasive fungal infections." Therapeutics and clinical risk management vol. 12 (2016): 1197-206. doi: https://doi.org/10.2147/TCRM.S90335
Wilson DT, Dimondi VP, Johnson SW, Jones TM, Drew RH. Role of isavuconazole in the treatment of invasive fungal infections. Ther Clin Risk Manag. 2016 Aug 03;12:1197-206. doi: 10.2147/TCRM.S90335. eCollection 2016. PMID: 27536124; PMCID: PMC4977098.
Copy Download .nbib Format: NLM
Deletion of .

Microbial cell (Graz, Austria)

Chin C, Donaghey F, Helming K, McCarthy M, Rogers S, Austriaco N.
PMID: 28357223
Microb Cell. 2014 Jan 15;1(2):58-63. doi: 10.15698/mic2014.01.119.

Caspofungin was the first member of a new class of antifungals called echinocandins to be approved by a drug regulatory authority. Like the other echinocandins, caspofungin blocks the synthesis of β(1,3)-D-glucan of the fungal cell wall by inhibiting the...

Cite
Chin C, Donaghey F, Helming K, et al. Deletion of . Microb Cell. 2014;1(2):58-63doi: 10.15698/mic2014.01.119.
Chin, C., Donaghey, F., Helming, K., McCarthy, M., Rogers, S., & Austriaco, N. (2014). Deletion of . Microbial cell (Graz, Austria), 1(2), 58-63. https://doi.org/10.15698/mic2014.01.119
Chin, Christopher, et al. "Deletion of ." Microbial cell (Graz, Austria) vol. 1,2 (2014): 58-63. doi: https://doi.org/10.15698/mic2014.01.119
Chin C, Donaghey F, Helming K, McCarthy M, Rogers S, Austriaco N. Deletion of . Microb Cell. 2014 Jan 15;1(2):58-63. doi: 10.15698/mic2014.01.119. PMID: 28357223; PMCID: PMC5348969.
Copy Download .nbib Format: NLM
Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia.

Blood research

Lee KH, Lim YT, Hah JO, Kim YK, Lee CH, Lee JM.
PMID: 29043231
Blood Res. 2017 Sep;52(3):167-173. doi: 10.5045/br.2017.52.3.167. Epub 2017 Sep 25.

BACKGROUND: Invasive fungal infections (IFIs) are a life-threatening problem in immunocompromised patients. Despite timely diagnosis and appropriate antifungal therapy, clinical outcomes of IFIs remain unsatisfactory, necessitating treatment with a combination of antifungal agents. Therefore, childhood leukemic patients treated with...

Cite
Lee KH, Lim YT, Hah JO, et al. Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia. Blood Res. 2017;52(3):167-173doi: 10.5045/br.2017.52.3.167.
Lee, K. H., Lim, Y. T., Hah, J. O., Kim, Y. K., Lee, C. H., & Lee, J. M. (2017). Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia. Blood research, 52(3), 167-173. https://doi.org/10.5045/br.2017.52.3.167
Lee, Kyu Ho, et al. "Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia." Blood research vol. 52,3 (2017): 167-173. doi: https://doi.org/10.5045/br.2017.52.3.167
Lee KH, Lim YT, Hah JO, Kim YK, Lee CH, Lee JM. Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia. Blood Res. 2017 Sep;52(3):167-173. doi: 10.5045/br.2017.52.3.167. Epub 2017 Sep 25. PMID: 29043231; PMCID: PMC5641508.
Copy Download .nbib Format: NLM
Correction: The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards.

PloS one

[No authors listed]
PMID: 26098116
PLoS One. 2015 Jun 22;10(6):e0131264. doi: 10.1371/journal.pone.0131264. eCollection 2015.

No abstract available.

Cite
Correction: The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards. PLoS One. 2015;10(6):e0131264doi: 10.1371/journal.pone.0131264.
(2015). Correction: The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards. PloS one, 10(6), e0131264. https://doi.org/10.1371/journal.pone.0131264
"Correction: The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards." PloS one vol. 10,6 (2015): e0131264. doi: https://doi.org/10.1371/journal.pone.0131264
Correction: The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards. PLoS One. 2015 Jun 22;10(6):e0131264. doi: 10.1371/journal.pone.0131264. eCollection 2015. PMID: 26098116; PMCID: PMC4476753.
Copy Download .nbib Format: NLM
Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies: A retrospective study.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale

Shalhoub S, Wang L, Ching A, Husain S, Rotstein C.
PMID: 25587291
Can J Infect Dis Med Microbiol. 2014 Nov-Dec;25(6):299-304. doi: 10.1155/2014/983724.

BACKGROUND: Invasive fungal infections are associated with morbidity and mortality in neutropenia secondary to hematological malignancies. Empirical antifungal agents are used to reduce their consequences. Caspofungin is the only echinocandin approved for this indication. Micafungin was compared with caspofungin...

Cite
Shalhoub S, Wang L, Ching A, et al. Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies: A retrospective study. Can J Infect Dis Med Microbiol. 2014;25(6):299-304doi: 10.1155/2014/983724.
Shalhoub, S., Wang, L., Ching, A., Husain, S., & Rotstein, C. (2014). Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies: A retrospective study. The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 25(6), 299-304. https://doi.org/10.1155/2014/983724
Shalhoub, Sarah, et al. "Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies: A retrospective study." The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale vol. 25,6 (2014): 299-304. doi: https://doi.org/10.1155/2014/983724
Shalhoub S, Wang L, Ching A, Husain S, Rotstein C. Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies: A retrospective study. Can J Infect Dis Med Microbiol. 2014 Nov-Dec;25(6):299-304. doi: 10.1155/2014/983724. PMID: 25587291; PMCID: PMC4277157.
Copy Download .nbib Format: NLM
Two echinocandin-resistant Candida glabrata FKS mutants from South Africa.

Medical mycology case reports

Naicker SD, Magobo RE, Zulu TG, Maphanga TG, Luthuli N, Lowman W, Govender NP.
PMID: 27069849
Med Mycol Case Rep. 2016 Mar 21;11:24-6. doi: 10.1016/j.mmcr.2016.03.004. eCollection 2016 Mar.

Echinocandins are recommended as first-line agents to treat invasive infections caused by Candida glabrata since this organism is inherently less susceptible to azoles. However, resistance to echinocandins has been described in C. glabrata due to amino acid changes in...

Cite
Naicker SD, Magobo RE, Zulu TG, et al. Two echinocandin-resistant Candida glabrata FKS mutants from South Africa. Med Mycol Case Rep. 2016;11:24-6doi: 10.1016/j.mmcr.2016.03.004.
Naicker, S. D., Magobo, R. E., Zulu, T. G., Maphanga, T. G., Luthuli, N., Lowman, W., & Govender, N. P. (2016). Two echinocandin-resistant Candida glabrata FKS mutants from South Africa. Medical mycology case reports, 1124-6. https://doi.org/10.1016/j.mmcr.2016.03.004
Naicker, Serisha D, et al. "Two echinocandin-resistant Candida glabrata FKS mutants from South Africa." Medical mycology case reports vol. 11 (2016): 24-6. doi: https://doi.org/10.1016/j.mmcr.2016.03.004
Naicker SD, Magobo RE, Zulu TG, Maphanga TG, Luthuli N, Lowman W, Govender NP. Two echinocandin-resistant Candida glabrata FKS mutants from South Africa. Med Mycol Case Rep. 2016 Mar 21;11:24-6. doi: 10.1016/j.mmcr.2016.03.004. eCollection 2016 Mar. PMID: 27069849; PMCID: PMC4811853.
Copy Download .nbib Format: NLM
The role of murine models in the development of antifungal therapy for systemic mycoses.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Graybill JR.
PMID: 11498404
Drug Resist Updat. 2000 Dec;3(6):364-383. doi: 10.1054/drup.2000.0171.

Animal testing is crucial to the development of new antifungal compounds. This review describes the role that murine and other animal models have played in the development of three classes of antifungal agents: the polyenes, the triazoles and the...

Cite
Graybill JR. The role of murine models in the development of antifungal therapy for systemic mycoses. Drug Resist Updat. 2000;3(6):364-383doi: 10.1054/drup.2000.0171.
Graybill, J. R. (2000). The role of murine models in the development of antifungal therapy for systemic mycoses. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 3(6), 364-383. https://doi.org/10.1054/drup.2000.0171
Graybill, John R.. "The role of murine models in the development of antifungal therapy for systemic mycoses." Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy vol. 3,6 (2000): 364-383. doi: https://doi.org/10.1054/drup.2000.0171
Graybill JR. The role of murine models in the development of antifungal therapy for systemic mycoses. Drug Resist Updat. 2000 Dec;3(6):364-383. doi: 10.1054/drup.2000.0171. PMID: 11498404.
Copy Download .nbib Format: NLM
[Changing epidemiological aspects of candidemia and their clinical and therapeutic implications].

Enfermedades infecciosas y microbiologia clinica

Salavert Lletí M, Jarque Ramos I, Pemán García J.
PMID: 17125667
Enferm Infecc Microbiol Clin. 2006 Oct;24:36-45. doi: 10.1157/13094277.

Candida species are a major cause of healthcare-related bloodstream and invasive infections. Studies assessing nosocomial bloodstream infections during the two last decades ranked Candida species as the fourth most common nosocomial bloodstream pathogen. The incidence of Candida species has...

Cite
Salavert Lletí M, Jarque Ramos I, Pemán García J. Los aspectos epidemiológicos cambiantes de la candidemia y sus implicaciones clinicoterapéuticas. [Changing epidemiological aspects of candidemia and their clinical and therapeutic implications]. Enferm Infecc Microbiol Clin. 2006;24:36-45doi: 10.1157/13094277.
Salavert Lletí, M., Jarque Ramos, I., & Pemán García, J. (2006). Los aspectos epidemiológicos cambiantes de la candidemia y sus implicaciones clinicoterapéuticas. [Changing epidemiological aspects of candidemia and their clinical and therapeutic implications]. Enfermedades infecciosas y microbiologia clinica, 2436-45. https://doi.org/10.1157/13094277
Salavert Lletí, Miguel, et al. "Los aspectos epidemiológicos cambiantes de la candidemia y sus implicaciones clinicoterapéuticas." [Changing epidemiological aspects of candidemia and their clinical and therapeutic implications]. Enfermedades infecciosas y microbiologia clinica vol. 24 (2006): 36-45. doi: https://doi.org/10.1157/13094277
Salavert Lletí M, Jarque Ramos I, Pemán García J. Los aspectos epidemiológicos cambiantes de la candidemia y sus implicaciones clinicoterapéuticas. [Changing epidemiological aspects of candidemia and their clinical and therapeutic implications]. Enferm Infecc Microbiol Clin. 2006 Oct;24:36-45. doi: 10.1157/13094277. Spanish. PMID: 17125667.
Copy Download .nbib Format: NLM
Comparison of echinocandin antifungals.

Therapeutics and clinical risk management

Eschenauer G, Depestel DD, Carver PL.
PMID: 18360617
Ther Clin Risk Manag. 2007 Mar;3(1):71-97. doi: 10.2147/tcrm.2007.3.1.71.

The incidence of invasive fungal infections, especially those due to Aspergillus spp. and Candida spp., continues to increase. Despite advances in medical practice, the associated mortality from these infections continues to be substantial. The echinocandin antifungals provide clinicians with...

Cite
Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag. 2007;3(1):71-97doi: 10.2147/tcrm.2007.3.1.71.
Eschenauer, G., Depestel, D. D., & Carver, P. L. (2007). Comparison of echinocandin antifungals. Therapeutics and clinical risk management, 3(1), 71-97. https://doi.org/10.2147/tcrm.2007.3.1.71
Eschenauer, Gregory, et al. "Comparison of echinocandin antifungals." Therapeutics and clinical risk management vol. 3,1 (2007): 71-97. doi: https://doi.org/10.2147/tcrm.2007.3.1.71
Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag. 2007 Mar;3(1):71-97. doi: 10.2147/tcrm.2007.3.1.71. PMID: 18360617; PMCID: PMC1936290.
Copy Download .nbib Format: NLM
Echinocandins: A ray of hope in antifungal drug therapy.

Indian journal of pharmacology

Grover ND.
PMID: 20606829
Indian J Pharmacol. 2010 Feb;42(1):9-11. doi: 10.4103/0253-7613.62396.

Invasive fungal infections are on the rise. Amphotericin B and azole antifungals have been the mainstay of antifungal therapy so far. The high incidence of infusion related toxicity and nephrotoxicity with amphotericin B and the emergence of fluconazole resistant...

Cite
Grover ND. Echinocandins: A ray of hope in antifungal drug therapy. Indian J Pharmacol. 2010;42(1):9-11doi: 10.4103/0253-7613.62396.
Grover, N. D. (2010). Echinocandins: A ray of hope in antifungal drug therapy. Indian journal of pharmacology, 42(1), 9-11. https://doi.org/10.4103/0253-7613.62396
Grover, Neeta D. "Echinocandins: A ray of hope in antifungal drug therapy." Indian journal of pharmacology vol. 42,1 (2010): 9-11. doi: https://doi.org/10.4103/0253-7613.62396
Grover ND. Echinocandins: A ray of hope in antifungal drug therapy. Indian J Pharmacol. 2010 Feb;42(1):9-11. doi: 10.4103/0253-7613.62396. PMID: 20606829; PMCID: PMC2885632.
Copy Download .nbib Format: NLM
Fungal echinocandin resistance.

F1000 biology reports

Munro CA.
PMID: 21173867
F1000 Biol Rep. 2010 Sep 08;2:66. doi: 10.3410/B2-66.

Echinocandins are the most recent introduction to the antifungal armamentarium and target the synthesis of β-(1,3)-glucan, the major structural polysaccharide of the fungal cell wall. Mechanisms have been identified that reduce the efficacy of the echinocandins: mutations of the...

Cite
Munro CA. Fungal echinocandin resistance. F1000 Biol Rep. 2010;2:66doi: 10.3410/B2-66.
Munro, C. A. (2010). Fungal echinocandin resistance. F1000 biology reports, 266. https://doi.org/10.3410/B2-66
Munro, Carol A. "Fungal echinocandin resistance." F1000 biology reports vol. 2 (2010): 66. doi: https://doi.org/10.3410/B2-66
Munro CA. Fungal echinocandin resistance. F1000 Biol Rep. 2010 Sep 08;2:66. doi: 10.3410/B2-66. PMID: 21173867; PMCID: PMC2990507.
Copy Download .nbib Format: NLM
Total synthesis of echinocandins. I. Stereocontrolled syntheses of the constituent amino acids.

Journal of the American Chemical Society

Kurokawa N, Ohfune Y.
PMID: 22175372
J Am Chem Soc. 1986 Sep 01;108(19):6041-3. doi: 10.1021/ja00279a064.

No abstract available.

Cite
Kurokawa N, Ohfune Y. Total synthesis of echinocandins. I. Stereocontrolled syntheses of the constituent amino acids. J Am Chem Soc. 1986;108(19):6041-3doi: 10.1021/ja00279a064.
Kurokawa, N., & Ohfune, Y. (1986). Total synthesis of echinocandins. I. Stereocontrolled syntheses of the constituent amino acids. Journal of the American Chemical Society, 108(19), 6041-3. https://doi.org/10.1021/ja00279a064
Kurokawa, N, and Ohfune, Y. "Total synthesis of echinocandins. I. Stereocontrolled syntheses of the constituent amino acids." Journal of the American Chemical Society vol. 108,19 (1986): 6041-3. doi: https://doi.org/10.1021/ja00279a064
Kurokawa N, Ohfune Y. Total synthesis of echinocandins. I. Stereocontrolled syntheses of the constituent amino acids. J Am Chem Soc. 1986 Sep 01;108(19):6041-3. doi: 10.1021/ja00279a064. PMID: 22175372.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 229 entries